The Janus kinase inhibitor baricitinib has the potential to be “an important part of the treatment landscape” for juvenile arthritis, research suggests.

Infliximab appears efficacious for patients with juvenile-onset spondyloarthritis who have failed to respond to conventional treatment, phase 3 study findings show.

medwireNews : The EMA’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending that the indication for secukinumab should be expanded to include two types of juvenile idiopathic arthritis.

Authors: Orazio De Lucia, Angela Flavia Luppino, Francesca Pregnolato, Antonella Murgo, Irene Pontikaki, Maurizio Gattinara, Tania Ubiali, Rolando Cimaz & Roberto Caporali Abstract Objective Hip involvement in juvenile idiopathic arthritis (JIA) is one of most important causes of pain and disability.

Canakinumab, a human monoclonal antibody, has demonstrated efficacy and safety in clinical trials in patients with systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still’s disease (AOSD). 

medwireNews : The EMA’s Committee for Medicinal Products for Human Use has recommended that the indication for tofacitinib should be expanded to include juvenile idiopathic arthritis (JIA) and juvenile psoriatic arthritis (PsA).

Children and adolescents with juvenile psoriatic arthritis or enthesitis-related arthritis may benefit from treatment with the IL-17A inhibitor secukinumab, indicate phase 3 study results.

Tofacitinib is effective for reducing the risk for disease flare in patients with polyarticular juvenile idiopathic arthritis, results of a randomized phase III study show.

Georgia World Congress Center, Atlanta, USA Presenting author:  Grant Schulert, USA What our Editorial Board said: This abstract is important because lung disease in systemic juvenile idiopathic arthritis is increasingly being recognized as an important cause of death.

Sangeeta Sule gives a pediatric rheumatologist’s view on a trial looking at tofacitinib for the treatment  of polyarticular juvenile idiopathic arthritis and the potential implementation of the results in the clinic (2:55).

Sangeeta Sule discusses the current recommendations for physical activity in children with juvenile idiopathic arthritis.

Sangeeta Sule discusses the current recommendations for physical activity in children with juvenile idiopathic arthritis.

Mamyrova G et al. Rheumatology (Oxford) 2018. doi: 10.1093/rheumatology/key190

Sunday,   November 10, 17:00–17:15. Georgia World Congress Center, Atlanta, USA Presenting author:  Grant Schulert, USA What our Editorial Board said: This abstract is important because lung disease in systemic juvenile idiopathic arthritis is increasingly being recognized as an important cause of death. Being able to identify which patients may be at increased risk for this complication is important. –  Sangeeta Sule, USA

Johannes Roth outlines the rationale behind the use of musculoskeletal ultrasonography in children with juvenile idiopathic arthritis, including enhancement of clinical assessment as part of a treat-to-target approach.

Johannes Roth outlines the rationale behind the use of musculoskeletal ultrasonography in children with juvenile idiopathic arthritis, including enhancement of clinical assessment as part of a treat-to-target approach.

The authors provide an overview of temporomandibular joint involvement in children with juvenile idiopathic arthritis, including imaging methods for diagnosis, clinical examination recommendations, and treatment options.

The authors provide an overview of temporomandibular joint involvement in children with juvenile idiopathic arthritis, including imaging methods for diagnosis, clinical examination recommendations, and treatment options.

In this editorial, Matthew Stoll explores the role of the microbiota in the pathogenesis of juvenile idiopathic arthritis, as well as current research into therapeutic alterations of the microbiome.